Display Settings:

Format

Send to:

Choose Destination
    Case Rep Oncol. 2009 Dec 11;2(3):234-241.

    Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate.

    Source

    Hospital de Dénia, Marina Salud, Dénia, Valencia, Spain.

    Abstract

    Patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapsed disease, including those patients with refractory disease after bone marrow transplantation. Targeted therapies have changed the standard of care for many advanced solid tumors. We have identified, in the literature, potential targets for the treatment of refractory germ cell tumors, and applied to a patient with a refractory disease. We chose sunitinib for this purpose. To our knowledge, this is the first case to be treated with sunitinib, and we have found a promising activity.

    PMID:
    20737043
    [PubMed]
    PMCID:
    PMC2914388
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Fig. 2
    Fig. 1

      Supplemental Content

      Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk